Qué cambió
Qué cambióUnitedHealth Group reported adjusted net earnings of $4.69 per share for the third quarter 2026. Revenue was $112.7 billion, slightly below $113.2 billion in the comparable quarter 2025. The operating cost ratio fell to 12.8% from 13.5%, and the medical cost ratio fell to 88.4% from 89.9%. The debt‑to‑capital ratio rose to 41.7% as of September 30, 2026. The company repurchased $5.0 billion of its common stock and paid $6.2 billion in dividends year to date.

Historial de la empresa
Octubre 2026
UNITEDHEALTH GROUP INC: 12 recorded developments from 3 official sources in 2026-10.
- 2026-10-13: The year-over-year decrease in medical care ratio was driven by medical cost management initiatives, benefit design changes and pricing discipline, as well as care delivery enhancements focused on affordability and integrated value-based care. Fuente
- 2026-10-13: The third quarter 2026 operating cost ratio was 12.8% compared to 13.5% in the third quarter 2025, reflecting realized operating efficiencies partially offset by accelerating investments in technology, processes and people to improve care delivery and consumer and clinician experiences. Fuente
- 2026-10-13: Optum Health’s third quarter 2026 revenues of $22.9 billion decreased 10% year-over-year as a result of fewer value-based care patients served in markets where Optum lacked sufficient value-based care presence to sustain its clinicians. Fuente
- 2026-10-13: UnitedHealth Group’s medical cost ratio was 88.4% for the third quarter 2026, reflecting both medical cost management and pricing discipline, as well as benefit design changes and care delivery enhancements focused on affordability and integrated value-based care. Fuente
- 2026-10-13: Affordability, Rural Care and Benefits The company is removing prior approval requirements, standardizing approval processes across the industry, reducing paperwork requirements and increasing transparency into the approval process, making it quicker and simpler for clinicians to treat p Fuente
- 2026-10-13: Approval Reform To combat high prescription drug costs, the company is lowering out-of-pocket costs for patients and bringing greater transparency to pharmacy benefits, setting a new standard for the industry. Fuente
- 2026-10-13: Expanding eligibility for UnitedHealthcare’s Gold Card status – exempting high-performing clinicians from routine approval requirements entirely – and removing requirements for home health services, eliminating nearly 10% of total UnitedHealthcare prior approval volume. Fuente
- 2026-10-13: Released an independent review of the HouseCalls program that showed the sampled diagnoses were overwhelmingly supported by medical records, with an error rate nearly three times lower than the rate reported by recent Federal CMS audits. Fuente
- 2026-10-13: The third quarter 2026 operating cost ratio was 12.8% compared to 13.5% in the third quarter 2025, reflecting realized operating efficiencies partially offset by accelerating investments in technology, processes and people to improve care delivery and consumer and clinician experiences. Fuente
- 2026-10-13: Launched the industry’s first fully transparent, fee-based pharmacy care model to bring greater clarity, predictability and affordability by decoupling PBM pricing from drug list prices and prescription volume, aligning incentives with patients and plan sponsors and introducing digital t Fuente
- 2026-10-13: Optum Health’s third quarter 2026 revenues of $22.9 billion decreased 10% year-over-year as a result of fewer value-based care patients served in markets where Optum lacked sufficient value-based care presence to sustain its clinicians. Fuente
- 2026-10-13: UnitedHealth Group Incorporated issued a press release announcing its third quarter 2026 results on October 13, 2026. Fuente
Los registros mensuales los redacta la IA a partir de los informes y fuentes oficiales verificados de cada mes (en inglés, tal como se extrajeron), y cada línea enlaza su fuente; las líneas argumentales agrupan hechos relacionados entre análisis mediante embeddings vectoriales (Amazon Titan Text Embeddings V2). Contexto provisional, no es asesoramiento de inversión.
Comparables del sector
Comparación con 36 empresas seguidas en Salud (mediana de ingresos +7,2% a/a), según datos XBRL de la SEC.
| Empresa | Últimos ingresos | Ingresos a/a | Margen operativo |
|---|
| Unitedhealth Group Inc UNH | 113 mil M $ | -0,4% | 5,8% |
| Mckesson Corp MCK | 111 mil M $ | +7,6% | 1,4% |
| CVS Health Corp CVS | 108 mil M $ | +5,4% | 3,3% |
| Cigna Group CI | 73,7 mil M $ | +5,6% | 3,3% |
| Cardinal Health Inc CAH | 67,5 mil M $ | +5,5% | 1,1% |
| Elevance Health, Inc. ELV | 51,4 mil M $ | +1,4% | 2,5% |
| Johnson & Johnson JNJ | 25,4 mil M $ | +5,9% | — |
Último periodo reportado por empresa en SEC CompanyFacts (XBRL). Los calendarios fiscales pueden diferir.
Expectativas y realidad
Abiertas
Updated Full Year 2026 Earnings Outlook to At Least $19.50 Per Share; Adjusted Earnings of At Least $20.50 Per Share
Dicho el 13 de octubre de 2026 · Periodo indicado: Full Year 2026 · Fuente · Nuestro análisis
Aún no contrastada con informes posteriores.
Announced nationwide coverage expansion for doula care with employer-sponsored plans, with more than 7 million members eligible for coverage by January 2027.
Dicho el 13 de octubre de 2026 · Periodo indicado: January 2027 · Fuente · Nuestro análisis
Aún no contrastada con informes posteriores.
Continued actions the company has taken to address these challenges include the below, with further commitments expected in 2027.
Dicho el 13 de octubre de 2026 · Periodo indicado: 2027 · Fuente · Nuestro análisis
Aún no contrastada con informes posteriores.
Committed to voluntarily eliminating and rebating profits from individual Affordable Care Act coverage offerings in 2026, returning this money directly to approximately 1 million ACA members as Congress works toward longer-term solutions to strengthen the stability and affordability of these plans.
Dicho el 13 de octubre de 2026 · Periodo indicado: 2026 · Fuente · Nuestro análisis
Aún no contrastada con informes posteriores.
The company now expects full year 2026 adjusted net earnings of at least $20.50 per share, incorporating experience through the third quarter 2026.
Dicho el 13 de octubre de 2026 · Periodo indicado: full year 2026 · Fuente · Nuestro análisis
Aún no contrastada con informes posteriores.
The company continues to target a long-term debt-to-capital ratio of approximately 40.0% by year-end.
Dicho el 13 de octubre de 2026 · Fuente · Nuestro análisis
Aún no contrastada con informes posteriores.
Mostrar todas (7)
Committed to 100% pass-through of manufacturer drug rebate discounts to clients by January 1, 2028.
Dicho el 13 de octubre de 2026 · Fuente · Nuestro análisis
Aún no contrastada con informes posteriores.
Lo que la dirección dijo que cabía esperar en los propios documentos de la empresa (objetivos, planes, previsiones; en inglés, tal como se extrajo), con la fecha y el periodo indicado. Las valoraciones las escribe la IA a partir de informes posteriores: provisionales, no revisadas por un editor, y un informe posterior coherente no es una prueba. La decisión de un editor las sustituye.
Hechos de gobierno corporativo
Documentos sobre cómo se dirige la empresa: cambios de auditor, reformulaciones, cambios en la dirección, informes tardíos, exclusiones de cotización, participaciones del Schedule 13D y cartas de la SEC, de la más reciente a la más antigua.
| Fecha | Hecho | Declaración |
|---|
| 9 de noviembre de 2026 | Salida o nombramiento de un consejero o directivo (8-K punto 5.02) | 8-K |
Tal como se presentó a la SEC, leído por código. Una carta de comentarios forma parte de la revisión habitual de la SEC y no implica por sí sola un problema; el punto 5.02 incluye nombramientos y salidas; el Form 25 puede referirse a un bono u otra clase de valores.
Grandes fondos (13F)
| Fondo | Acciones | Valor | Cambio en acciones | Trimestre |
|---|
| BlackRock | 77.211.952 | $28.342.963.233 | +0,5% | T3 2026 |
| State Street | 45.703.591 | $16.776.874.184 | +0,2% | T3 2026 |
| Fidelity (FMR) | 31.060.207 | $11.401.580.315 | +11,0% | T3 2026 |
| Geode Capital Management | 20.745.390 | $7.580.119.656 | -4,6% | T3 2026 |
| Norges Bank (Norway's sovereign fund) | 12.736.973 | $5.293.868.088 | — | T2 2026 |
| Wellington Management | 10.865.278 | $3.988.426.249 | +1,8% | T3 2026 |
| Capital Research Global Investors | 8.634.268 | $3.170.024.243 | -18,0% | T3 2026 |
| Renaissance Technologies | 2.226.720 | $817.384.838 | +506,7% | T3 2026 |
| Citadel Advisors | 2.035.293 | $747.115.354 | +91,3% | T3 2026 |
| Millennium Management | 1.241.266 | $455.643.923 | -23,3% | T3 2026 |
| D. E. Shaw & Co. | 428.766 | $157.391.423 | -13,2% | T3 2026 |
| Two Sigma Investments | 379.884 | $139.447.819 | +93,1% | T3 2026 |
| Tiger Global Management | 297.452 | $109.188.679 | 0,0% | T3 2026 |
| Appaloosa (David Tepper) | 90.000 | $24.353.100 | — | T1 2026 |
| Bridgewater Associates | 51.713 | $18.982.808 | +734,5% | T3 2026 |
De los informes trimestrales 13F-HR de los grandes fondos que seguimos, tal como se presentaron. Los fondos informan hasta 45 días después del cierre del trimestre, por lo que las posiciones pueden haber cambiado. Cambio: frente al trimestre anterior del mismo fondo. No es una recomendación.